{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:06:35Z","timestamp":1785855995465,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28005","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T12:48:18Z","timestamp":1710593298000},"page":"e28005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pan-cancer identified ARPC1B as a promising target for tumor immunotherapy and prognostic biomarker, particularly in READ"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8885","authenticated-orcid":false,"given":"Chenxiong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2024.e28005_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e28005_bib2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"6165","key":"10.1016\/j.heliyon.2024.e28005_bib3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1126\/science.1249481","article-title":"Cancer immunotherapy","volume":"342","author":"McNutt","year":"2013","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28005_bib4","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1167\/iovs.05-0810","article-title":"Arpc1b gene is a candidate prediction marker for choroidal malignant melanomas sensitive to radiotherapy","volume":"47","author":"Kumagai","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28005_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1083\/jcb.138.2.375","article-title":"The human Arp2\/3 complex is composed of evolutionarily conserved subunits and is localized to cellular regions of dynamic actin filament assembly","volume":"138","author":"Welch","year":"1997","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e28005_bib6","article-title":"A comprehensive prognostic and immunological analysis of a six-gene signature associated with glycolysis and immune response in uveal melanoma","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28005_bib7","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.3892\/ol.2017.5798","article-title":"Molecular dysexpression in gastric cancer revealed by integrated analysis of transcriptome data","volume":"13","author":"Li","year":"2017","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28005_bib8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/mc.22534","article-title":"Low-frequency nonsynonymous variants in FKBPL and ARPC1B genes are associated with breast cancer risk in Chinese women","volume":"56","author":"Zhou","year":"2017","journal-title":"Mol. Carcinog."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e28005_bib9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s00405-015-3703-9","article-title":"Caveolin 1 (Cav-1) and actin-related protein 2\/3 complex, subunit 1B (ARPC1B) expressions as prognostic indicators for oral squamous cell carcinoma (OSCC)","volume":"273","author":"Auzair","year":"2016","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28005_bib10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.heliyon.2024.e28005_bib11","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3389\/fimmu.2020.02048","article-title":"Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28005_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s10388-020-00796-9","article-title":"Pan-cancer analysis identifies ESM1 as a novel oncogene for esophageal cancer","volume":"18","author":"Cui","year":"2021","journal-title":"Esophagus"},{"key":"10.1016\/j.heliyon.2024.e28005_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.569887","article-title":"Pan-cancer analysis of the mitophagy-related protein PINK1 as a biomarker for the immunological and prognostic role","volume":"10","author":"Zhu","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28005_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.7150\/jca.50785","article-title":"Immunological role and prognostic value of APBB1IP in pan-cancer analysis","volume":"12","author":"Ge","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e28005_bib15","volume":"vol. 2017","author":"Bonneville","year":"2017"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28005_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1160\/TH14-04-0298","article-title":"The role of actin-binding proteins in the control of endothelial barrier integrity","volume":"113","author":"Garcia-Ponce","year":"2015","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28005_bib18","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018267","article-title":"The actin cytoskeleton and actin-based motility","volume":"10","author":"Svitkina","year":"2018","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.heliyon.2024.e28005_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.701065","article-title":"Identification of tumor antigens and immune landscape in glioblastoma for mRNA vaccine development","volume":"12","author":"Ye","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.heliyon.2024.e28005_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28005_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.6004\/jnccn.2018.7070","article-title":"Response to anti-PD-1 in uveal melanoma without high-volume liver metastasis","volume":"17","author":"Johnson","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28005_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/path.5213","article-title":"Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities","volume":"247","author":"Rabbie","year":"2019","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28005_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000508383","article-title":"Clinical trials in metastatic uveal melanoma: current status","volume":"6","author":"Sussman","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.heliyon.2024.e28005_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.exer.2019.01.004","article-title":"Identification of a nine-miRNA signature for the prognosis of Uveal Melanoma","volume":"180","author":"Xin","year":"2019","journal-title":"Exp. Eye Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28005_bib25","first-page":"195","article-title":"Oral cancer and precancerous lesions","volume":"52","author":"Neville","year":"2002","journal-title":"CA Cancer J Clin"},{"issue":"Suppl","key":"10.1016\/j.heliyon.2024.e28005_bib26","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.14219\/jada.archive.2001.0382","article-title":"Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge","volume":"132","author":"Silverman","year":"2001","journal-title":"J. Am. Dent. Assoc."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28005_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/medicina56010015","article-title":"Tumor microenvironment","volume":"56","author":"Arneth","year":"2019","journal-title":"Medicina"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28005_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28005_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28005_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2031499","article-title":"Dual role of ARPC1B in regulating the network between tumor-associated macrophages and tumor cells in glioblastoma","volume":"11","author":"Liu","year":"2022","journal-title":"OncoImmunology"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e28005_bib32","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-05-2566","article-title":"Coexpression of actin-related protein 2 and Wiskott-Aldrich syndrome family verproline-homologous protein 2 in adenocarcinoma of the lung","volume":"12","author":"Semba","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e28005_bib33","doi-asserted-by":"crossref","first-page":"42983","DOI":"10.18632\/oncotarget.17785","article-title":"Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28005_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e28005_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102084","article-title":"Impact of high tumor mutational burden in solid tumors and challenges for biomarker application","volume":"89","author":"McNamara","year":"2020","journal-title":"Cancer Treat Rev."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e28005_bib36","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28005_bib37","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28005_bib38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28005_bib39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28005_bib40","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAI.0000000000000575","article-title":"Microsatellite instability: a predictive biomarker for cancer immunotherapy","volume":"26","author":"Chang","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"14","key":"10.1016\/j.heliyon.2024.e28005_bib41","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","article-title":"CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set","volume":"72","author":"Reinhold","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28005_bib42","first-page":"45","article-title":"Silencing of the ARP2\/3 complex disturbs pancreatic cancer cell migration","volume":"33","author":"Rauhala","year":"2013","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e28005_bib43","article-title":"Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies","volume":"9","author":"Nishikawa","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28005_bib44","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1158\/2326-6066.CIR-17-0131","article-title":"Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction","volume":"5","author":"Colbeck","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2024.e28005_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ebiom.2019.08.025","article-title":"MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers","volume":"47","author":"Fultang","year":"2019","journal-title":"EBioMedicine"},{"issue":"52","key":"10.1016\/j.heliyon.2024.e28005_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024040362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024040362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:03:53Z","timestamp":1784207033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024040362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405844024040362"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28005","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pan-cancer identified ARPC1B as a promising target for tumor immunotherapy and prognostic biomarker, particularly in READ","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28005"}}